MK-0822
Total Payments
$123,719
Transactions
57
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $24.48 | 6 | 0 |
| 2017 | $123,694 | 51 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $121,254 | 52 | 98.0% |
| Consulting Fee | $2,465 | 5 | 2.0% |
Payments by Type
Research
$121,254
52 transactions
General
$2,465
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Double-Bblind, Randomized, Placebo-Controlled, Single Oral Rising-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of L-001037536 in Healthy Male Japanese Volunteers | Merck Sharp & Dohme Corporation | $112,049 | 0 |
| An Observational Follow-Up Study for A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Protocol 018 | Merck Sharp & Dohme Corporation | $4,180 | 0 |
| A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theEffects of Odanacatib MK-0822 on Bone Mineral Density BMD and Overall Safety inthe Treatment of Osteoporosis in Postmenopausal Women Previously Treated with anOral Bisphosphonate | Merck Sharp & Dohme Corporation | $3,200 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 Cathepsin-K Inhibitor in the Treatment of Postmenopausal Women With Osteoporosis | Merck Sharp & Dohme Corporation | $1,800 | 0 |
| A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium | Merck Sharp & Dohme Corporation | $24.48 | 0 |
Top Doctors Receiving Payments for MK-0822
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $123,719
Product Information
- Type Drug
- Total Payments $123,719
- Total Doctors 5
- Transactions 57
About MK-0822
MK-0822 is a drug associated with $123,719 in payments to 5 healthcare providers, recorded across 57 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $24.48 was paid across 6 transactions to 0 doctors.
The most common payment nature for MK-0822 is "Unspecified" ($121,254, 98.0% of total).
MK-0822 is associated with 5 research studies, including "A Double-Bblind, Randomized, Placebo-Controlled, Single Oral Rising-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of L-001037536 in Healthy Male Japanese Volunteers" ($112,049).